A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

Cell

Volumn 125, Issue 4, 2006, Pages 733-747

  Knight, Zachary A ^a   Gonzalez, Beatriz ^c   Feldman, Morri E ^a   Zunder, Eli R ^a   Goldenberg, David D ^b   Williams, Olusegun ^a   Loewith, Robbie ^d   Stokoe, David ^b   Balla, Andras ^e   Toth, Balazs ^e   Balla, Tamas ^e   Weiss, William A ^b   Williams, Roger L ^c   Shokat, Kevan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMA 37; CHROMONE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INSULIN; ISOENZYME; KU 55933; MORPHOLINE DERIVATIVE; P110ALPHA PROTEIN; P110BETA PROTEIN; P110GAMMA PROTEIN; PHENOL DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PI 103; PIK 124; PIK 39; PIK 75; PIK 90; PIK 93; PROTEIN DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; STEROID; TGX 286; THIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FAMILY; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 33646383684     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.03.035     Document Type: Article

References (50)

1. Alaimo P.J., Knight Z.A., and Shokat K.M. Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg. Med. Chem. 13 (2005) 2825-2836
2. Asano T., Kanda A., Katagiri H., Nawano M., Ogihara T., Inukai K., Anai M., Fukushima Y., Yazaki Y., Kikuchi M., et al. p110beta is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J. Biol. Chem. 275 (2000) 17671-17676
3. Barvian, N.C., Kolz, C.N., Para, K.S., Patt, W.C., and Viskick, M. June 2004. Benzoxazin-3-ones and derivatives thereof as inhibitors of PI3K. WO 04/052373.
4. Bi L., Okabe I., Bernard D.J., Wynshaw-Boris A., and Nussbaum R.L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274 (1999) 10963-10968
5. Bi L., Okabe I., Bernard D.J., and Nussbaum R.L. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome 13 (2002) 169-172
6. Brachmann S.M., Ueki K., Engelman J.A., Kahn R.C., and Cantley L.C. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25 (2005) 1596-1607
7. Bruce, I., Finan, P., Leblanc, C., McCarthy, C., Whitehead, L., Blair, N., Bloomfield, G., Hayler, J., Kirman, L., Oza, M., and Shukla, L. September 2003. 5-phenylthiazole derivatives and use as PI3 kinase inhibitors. WO 03/072557.
8. Camps M., Ruckle T., Ji H., Ardissone V., Rintelen F., Shaw J., Ferrandi C., Chabert C., Gillieron C., Francon B., et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11 (2005) 936-943
9. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 4240-4245
10. Condliffe A.M., Davidson K., Anderson K.E., Ellson C.D., Crabbe T., Okkenhaug K., Vanhaesebroeck B., Turner M., Webb L., Wymann M.P., et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 (2005) 1432-1440
11. Domin J., and Waterfield M.D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 410 (1997) 91-95
12. Fan Q.-W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3-kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
13. Feng J., Park J., Cron P., Hess D., and Hemmings B.A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 279 (2004) 41189-41196
14. Fruman D.A., Meyers R.E., and Cantley L.C. Phosphoinositide kinases. Annu. Rev. Biochem. 67 (1998) 481-507
15. Halbrook, J., Kesicki, E., Burgess, L.E., Schlachter, S.T., Eary, C.T., Schiro, J.G., Huang, H., Evans, M., and Han, Y. March 2002. Materials and methods to potentiate cancer treatment. WO 02/20500.
16. Harrington L.S., Findlay G.M., and Lamb R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30 (2005) 35-42
17. Hayakawa, M., Kaizawa, H., Kawaguchi, K., Matsuda, K., Ishikawa, N., Koizumi, T., Yamano, M., Okada, M., Ohta, M. January 2003a. Imidazopyridine derivatives. European patent 1,277,754.
18. Hayakawa, M., Kaizawa, H., Moritoma, H., Kawaguchi, K., Koizumi, T., Yamano, M., Matsuda, K., Okada, M., Ohta, M. January 2003b. Condensed heteroaryl derivatives. European patent 1,277,738.
19. Hickson I., Zhao Y., Richardson C.J., Green S.J., Martin N.M., Orr A.I., Reaper P.M., Jackson S.P., Curtin N.J., and Smith G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64 (2004) 9152-9159
20. Jackson, S.P., Robertson, A.D., Kenche, V., Thompson, P., Prabaharan, H., Anderson, K., Abbott, B. Goncalves, I., Nesbitt, W., Shoenwaelder, S., and Saylik, D. February 2004. Inhibition of phosphoinositide 3-kinase beta. WO 04/016607.
21. Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., Kenche V., Anderson K.E., Dopheide S.M., Yuan Y., et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med. 11 (2005) 507-514
22. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., and Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17 (2001) 615-675
23. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
24. Knight Z.A., Chiang G.G., Alaimo P.J., Kenski D.M., Ho C.B., Coan K., Abraham R.T., and Shokat K.M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12 (2004) 4749-4759
25. Lakshmanan J., Elmendorf J.S., and Ozcan S. Analysis of insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes. Methods Mol. Med. 83 (2003) 97-103
26. Lau A., Swinbank K.M., Ahmed P.S., Taylor D.L., Jackson S.P., Smith G.C., and O'Connor M.J. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat. Cell Biol. 7 (2005) 493-500
27. Luo J., Field S.J., Lee J.Y., Engelman J.A., and Cantley L.C. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J. Cell Biol. 170 (2005) 455-464
28. Madhusudan, Trafny E.A., Xuong N.H., Adams J.A., Teneyck L.F., Taylor S.S., and Sowadski J.M. cAMP-dependent protein-kinase-crystallographic insights into substrate recognition and phosphotransfer. Protein Sci. 3 (1994) 176-187
29. Patrucco E., Notte A., Barberis L., Selvetella G., Maffei A., Brancaccio M., Marengo S., Russo G., Azzolino O., Rybalkin S.D., et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 (2004) 375-387
30. Peng Y., Woods R.G., Beamish H., Ye R., Lees-Miller S.P., Lavin M.F., and Bedford J.S. Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM. Cancer Res. 65 (2005) 1670-1677
31. Robertson, A.D., Jackson, S., Kenche, V., Yaip, C., Parbaharan, H., and Thompson, P. July 2001. Therapeutic morpholino-substituted compounds. WO 01/53266.
32. Ruderman N.B., Kapeller R., White M.F., and Cantley L.C. Activation of phosphatidylinositol 3-kinase by insulin. Proc. Natl. Acad. Sci. USA 87 (1990) 1411-1415
33. Sadhu, C., Dick, K., Treiberg, J., Sowell, C., Kesicki, E.A., and Oliver, A. April 2001. Inhibitors of human phosphatidyl-inositol 3-kinase delta. WO 01/81346.
34. Sadhu C., Masinovsky B., Dick K., Sowell C.G., and Staunton D.E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 170 (2003) 2647-2654
35. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
36. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., and Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3 (1999) 639-648
37. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
38. Schmid A.C., Byrne R.D., Vilar R., and Woscholski R. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 566 (2004) 35-38
39. Serunian L.A., Auger K.R., and Cantley L.C. Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. Methods Enzymol. 198 (1991) 78-87
40. Shimada, M., Murata, T., Fuchikami, K., Tsujishita, H., Omori, N., Kato, I., Miura, M., Urbahns, K., Gantner, F., and Bacon, K. April 2004. Fused azole-pyrimidine derivatives. WO 04/029055.
41. Smith, G.C., Martin, N.M., Jackson, S.P., O'Connor, M.J., Lau, A.Y., Cockcroft, X.F., Matthews, I.T., Menear, K.A., Rigoreau, L.J., Hummerson, M.G., and Griffin, R.J. August 2003. Pyranones useful as ATM inhibitors. WO 03/070726.
42. Ueki K., Yballe C.M., Brachmann S.M., Vicent D., Watt J.M., Kahn C.R., and Cantley L.C. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 99 (2002) 419-424
43. Ueki K., Fruman D.A., Yballe C.M., Fasshauer M., Klein J., Asano T., Cantley L.C., and Kahn C.R. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J. Biol. Chem. 278 (2003) 48453-48466
44. Vanhaesebroeck B., Ali K., Bilancio A., Geering B., and Foukas L.C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30 (2005) 194-204
45. Viniegra J.G., Martinez N., Modirassari P., Losa J.H., Parada Cobo C., Lobo V.J., Luquero C.I., Alvarez-Vallina L., Ramon y Cajal S., Rojas J.M., and Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 280 (2005) 4029-4036
46. Walker E.H., Perisic O., Ried C., Stephens L., and Williams R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 (1999) 313-320
47. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6 (2000) 909-919
48. Ward S., Sotsios Y., Dowden J., Bruce I., and Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 10 (2003) 207-213
49. Yart A., Roche S., Wetzker R., Laffargue M., Tonks N., Mayeux P., Chap H., and Raynal P. A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J. Biol. Chem. 277 (2002) 21167-21178
50. Yu J., Zhang Y., McIlroy J., Rordorf-Nikolic T., Orr G.A., and Backer J.M. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18 (1998) 1379-1387